Genomics is a field of study focusing on genes and how they interact to impact disease. Translational research aims to adapt experimental findings into medical interventions. Translational genomics thus creates an integrative approach of applying genomic information to influence disease at a prevention, diagnosis, or treatment level.
On January 20, 2015, President Obama announced the Precision Medicine Initiative® (PMI) (link is external) in his State of the Union address. Through advances in research, technology and...
A number of recently publications have heralded the advent of Precision Medicine in Oncology, where next generation sequencing technology, other ’omics technologies, serial biopsies, so...
DATE: November 17th, 2015TIME: 8am PDT, 11am EDT, 4pm GMTBiobanks provide important capacity to collect large genomic data sets intended to enable the study of genetic signatures of an...
Introduction and adoption of whole-genome sequencing has enabled new methods of investigation in the quest for answers in diagnostic odyssey cases as well as in the broader study of genetic d...
Multidimensional molecular characterization has led to a tsunami of cancer data. Precision Medicine assumes that new understanding and better interventions will flow from this “Big Data...
Melanoma, a cancer of pigment-producing cells, accounts for nearly 200,000 new cases of cancer reported each year worldwide. It is the deadliest skin cancer. Alarmingly, in the U.S., the inci...
The process by which observations in the laboratory or the clinic are transformed into demonstrably useful interventions that tangibly improve human health is frequently termed "translation."...
Among many surprising insights, the genomic revolution has helped us to realize that we're never alone and, in fact, barely human. For most of our lives, we share our bodies with some ten ti...
DATE: June 17th, 2015TIME: 8am Pacific time, 11am Eastern timeSpatial heterogeneity of tumors has been identified within and between metastatic lesions and can be visualized wit...
With current NGS platforms, the boundaries of variant detection and gene content for genetic disease panels has been vastly expanded leading to increases in detection rates. However these pla...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Biological datasets have become increasing large and complex. Knowledge databases and publicly available datasets are available for use in experimental planning and running results comparison...
I will discuss recent statistical methods for identifying differentially expressed genes in static and time course bulk RNA-seq experiments. I will also provide an overview of the opportunit...
In this presentation we will illustrate the advantages of AFA technology in clinically significant applications (NGS, FFPE, ChIP) and will demonstrate the flexibility of Covaris AFA in deliv...
The era of omics has ushered in the hope for personalized medicine. Proteomic and genomic strategies that allow unbiased identification of genes and proteins and their post-transcriptional a...
Illumina next-generation sequencing (NGS) and microarray technologies are revolutionizing cancer research, enabling cancer variant discovery and detection and molecular monitoring. Join u...
Proteomics technology has improved dramatically over the last decade. The technology developments have largely been directed around instrument hardware, where instruments have been developed...
The comprehensive, multidimensional molecular characterization of tumors and the individuals in which they have developed is transforming cancer definition, diagnosis, treatment, and preventi...
Next-generation sequencing (NGS) has revolutionized extraction of genomic information, facilitating rapid advances in the fields of clinical research and molecular diagnostics. However, c...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision-making. An...
As next-generation sequencing (NGS) platforms advance in their speed, ease-of-use, and cost-effectiveness, many translational researchers are transitioning from microarrays to RNA sequencing...
Master regulatory transcription factors localize to the genome in a manner influenced by chromatin accessibility and influencing global chromatin structure. With an interest in understanding...
This presentation will focus on NuMediis general approach towards the discovery of new therapeutic uses for existing drugs. While the business models for repurposing marketed drugs versus rep...
Patients with chromosomal rearrangements resulting in fusion proteins are among the most responsive to published targeted therapy. For example, targeting of the EML4-ALK fusion in non-small c...
On January 20, 2015, President Obama announced the Precision Medicine Initiative® (PMI) (link is external) in his State of the Union address. Through advances in research, technology and...
A number of recently publications have heralded the advent of Precision Medicine in Oncology, where next generation sequencing technology, other ’omics technologies, serial biopsies, so...
DATE: November 17th, 2015TIME: 8am PDT, 11am EDT, 4pm GMTBiobanks provide important capacity to collect large genomic data sets intended to enable the study of genetic signatures of an...
Introduction and adoption of whole-genome sequencing has enabled new methods of investigation in the quest for answers in diagnostic odyssey cases as well as in the broader study of genetic d...
Multidimensional molecular characterization has led to a tsunami of cancer data. Precision Medicine assumes that new understanding and better interventions will flow from this “Big Data...
Melanoma, a cancer of pigment-producing cells, accounts for nearly 200,000 new cases of cancer reported each year worldwide. It is the deadliest skin cancer. Alarmingly, in the U.S., the inci...
The process by which observations in the laboratory or the clinic are transformed into demonstrably useful interventions that tangibly improve human health is frequently termed "translation."...
Among many surprising insights, the genomic revolution has helped us to realize that we're never alone and, in fact, barely human. For most of our lives, we share our bodies with some ten ti...
DATE: June 17th, 2015TIME: 8am Pacific time, 11am Eastern timeSpatial heterogeneity of tumors has been identified within and between metastatic lesions and can be visualized wit...
With current NGS platforms, the boundaries of variant detection and gene content for genetic disease panels has been vastly expanded leading to increases in detection rates. However these pla...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Biological datasets have become increasing large and complex. Knowledge databases and publicly available datasets are available for use in experimental planning and running results comparison...
I will discuss recent statistical methods for identifying differentially expressed genes in static and time course bulk RNA-seq experiments. I will also provide an overview of the opportunit...
In this presentation we will illustrate the advantages of AFA technology in clinically significant applications (NGS, FFPE, ChIP) and will demonstrate the flexibility of Covaris AFA in deliv...
The era of omics has ushered in the hope for personalized medicine. Proteomic and genomic strategies that allow unbiased identification of genes and proteins and their post-transcriptional a...
Illumina next-generation sequencing (NGS) and microarray technologies are revolutionizing cancer research, enabling cancer variant discovery and detection and molecular monitoring. Join u...
Proteomics technology has improved dramatically over the last decade. The technology developments have largely been directed around instrument hardware, where instruments have been developed...
The comprehensive, multidimensional molecular characterization of tumors and the individuals in which they have developed is transforming cancer definition, diagnosis, treatment, and preventi...
Next-generation sequencing (NGS) has revolutionized extraction of genomic information, facilitating rapid advances in the fields of clinical research and molecular diagnostics. However, c...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision-making. An...
As next-generation sequencing (NGS) platforms advance in their speed, ease-of-use, and cost-effectiveness, many translational researchers are transitioning from microarrays to RNA sequencing...
Master regulatory transcription factors localize to the genome in a manner influenced by chromatin accessibility and influencing global chromatin structure. With an interest in understanding...
This presentation will focus on NuMediis general approach towards the discovery of new therapeutic uses for existing drugs. While the business models for repurposing marketed drugs versus rep...
Patients with chromosomal rearrangements resulting in fusion proteins are among the most responsive to published targeted therapy. For example, targeting of the EML4-ALK fusion in non-small c...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
